Differential vasoactive effects of oestrogen, oestrogen receptor agonists and selective oestrogen receptor modulators in rat middle cerebral artery

Neuroscience Research

Volumn 71, Issue 1, 2011, Pages 78-84

  Patkar, S ^a   Farr, T D ^b   Cooper, E ^b   Dowell, F J ^b   Carswell, H V O ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

17 oestradiol; Cerebrovasculature; ER 36 antibody; Oestrogen receptor; Selective oestrogen receptor modulator; Vasorelaxation

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA AGONIST; ESTROGEN RECEPTOR BETA AGONIST; FULVESTRANT; LY 2120310; LY 362321; N(G) NITROARGININE METHYL ESTER; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRIC OXIDE SYNTHASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL TONE; CELL MEMBRANE; DRUG RECEPTOR BINDING; MALE; MIDDLE CEREBRAL ARTERY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; ESTRADIOL CONGENERS; ESTROGENS; FEMALE; MALE; MIDDLE CEREBRAL ARTERY; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VASODILATION;

EID: 79960908086     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2011.05.006     Document Type: Article

References (58)

1. Arbuckle N.D., Dauvois S., Parker M.G. Effects of antioestrogens on the DNA binding activity of oestrogen receptors in vitro. Nucleic Acids Res. 1992, 20(15):3839-3844.
2. Aronica S.M., Kraus W.L., Katzenellenbogen B.S. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc. Natl. Acad. Sci. U.S.A. 1994, 91(18):8517-8521.
3. Austin C.E. Chronic and acute effects of oestrogens on vascular contractility. J. Hypertens. 2000, 18(10):1365-1378.
4. Barrett-Connor E., Bush T.L. Estrogen and coronary heart disease in women. JAMA 1991, 265(14):1861-1867.
5. Bayard F., Clamens S., Meggetto F., Blaes N., Delsol G., Faye J.C. Estrogen synthesis, estrogen metabolism, and functional estrogen receptors in rat arterial smooth muscle cells in culture. Endocrinology 1995, 136(4):1523-1529.
6. Bertelli G., Venturini M., Del Mastro L., Garrone O., Cosso M., Gustavino C., Cusimano E., Guido T., Nicolo G., Rosso R. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res. Treat. 1998, 47(1):41-46.
7. Bologa C.G., Revankar C.M., Young S.M., Edwards B.S., Arterburn J.B., Kiselyov A.S., Parker M.A., Tkachenko S.E., Savchuck N.P., Sklar L.A., Oprea T.I., Prossnitz E.R. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2006, 2(4):207-212.
8. Bulayeva N.N., Wozniak A.L., Lash L.L., Watson C.S. Mechanisms of membrane estrogen receptor-alpha-mediated rapid stimulation of Ca2+ levels and prolactin release in a pituitary cell line. Am. J. Physiol. Endocrinol. Metab. 2005, 288(2):E388-E397.
9. Carswell H.V., Anderson N.H., Morton J.J., McCulloch J., Dominiczak A.F., Macrae I.M. Investigation of estrogen status and increased stroke sensitivity on cerebral blood flow after a focal ischemic insult. J. Cereb. Blood Flow Metab. 2000, 20(6):931-936.
10. Carswell H.V., Macrae I.M., Farr T.D. Complexities of oestrogen in stroke. Clin. Sci. (Lond.) 2009, 118(6):375-389.
11. Cockell A.P., Poston L. 17Beta-estradiol stimulates flow-induced vasodilatation in isolated small mesenteric arteries from prepubertal femal rats. Am. J. Obstet. Gynecol. 1997, 177(6):1432-1438.
12. Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 1993, 106(Pt 4):1377-1388.
13. Falkeborn M., Persson I., Terent A., Adami H.O., Lithell H., Bergstrom R. Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden. Arch. Intern. Med. 1993, 153(10):1201-1209.
14. Farr T.D., Carswell H.V., McCann D.J., Sato M., Bryant H.U., Dodge J.A., Macrae I.M. The selective oestrogen receptor modulator, LY362321 is not neuroprotective in a rat model of transient focal ischaemia. J. Neuroendocrinol. 2008, 20(3):366-374. (369).
15. Fawell S.E., White R., Hoare S., Sydenham M., Page M., Parker M.G. Inhibition of estrogen receptor-DNA binding by the " pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. U.S.A. 1990, 87(17):6883-6887.
16. Filardo E.J., Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol. Metab. 2005, 16(8):362-367.
17. Gordon K.B., Macrae I.M., Carswell H.V. Effects of 17beta-oestradiol on cerebral ischaemic damage and lipid peroxidation. Brain Res. 2005, 1036(1-2):155-162.
18. Hamilton C.A., Groves S., Carswell H.V., Brosnan M.J., Graham D., Dominiczak A.F. Estrogen treatment enhances nitric oxide bioavailability in normotensive but not hypertensive rats. Am. J. Hypertens. 2006, 19(8):859-866.
19. Hurn P.D., Littleton-Kearney M.T., Kirsch J.R., Dharmarajan A.M., Traystman R.J. Postischemic cerebral blood flow recovery in the female: effect of 17 beta-estradiol. J. Cereb. Blood Flow Metab. 1995, 15(4):666-672.
20. Kang L., Zhang X., Xie Y., Tu Y., Wang D., Liu Z., Wang Z.Y. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol. Endocrinol. 2010, 24(4):709-721.
21. Kannel W.B. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J. Cardiovasc. Risk 1994, 1(4):333-339.
22. Kitazawa T., Hamada E., Kitazawa K., Gaznabi A.K. Non-genomic mechanism of 17 beta-oestradiol-induced inhibition of contraction in mammalian vascular smooth muscle. J. Physiol. 1997, 499(Pt 2):497-511.
23. Kraichely D.M., Sun J., Katzenellenbogen J.A., Katzenellenbogen B.S. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology 2000, 141(10):3534-3545.
24. Landers J.P., Spelsberg T.C. New concepts in steroid hormone action: transcription factors, proto-oncogenes, and the cascade model for steroid regulation of gene expression. Crit. Rev. Eukaryot. Gene Expr. 1992, 2(1):19-63.
25. Lawrence J.E., Klein J.C., Carter J.R. Menstrual cycle elicits divergent forearm vascular responses to vestibular activation in humans. Auton. Neurosci. 2010, 154(1-2):89-93.
26. Leung H.S., Seto S.W., Kwan Y.W., Leung F.P., Au A.L., Yung L.M., Yao X., Huang Y. Endothelium-independent relaxation to raloxifene in porcine coronary artery. Eur. J. Pharmacol. 2007, 555(2-3):178-184.
27. Lewis J.S., Jordan V.C. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat. Res. 2005, 591(1-2):247-263.
28. Love R.R., Wiebe D.A., Feyzi J.M., Newcomb P.A., Chappell R.J. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl. Cancer Inst. 1994, 86(20):1534-1539.
29. McNeill A.M., Duckles S.P., Krause D.N. Relaxant effects of 17 beta-estradiol in the rat tail artery are greater in females than males. Eur. J. Pharmacol. 1996, 308(3):305-309.
30. McNeill A.M., Zhang C., Stanczyk F.Z., Duckles S.P., Krause D.N. Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke 2002, 33(6):1685-1691.
31. McNeish A.J., Dora K.A., Garland C.J. Possible role for K+ in endothelium-derived hyperpolarizing factor-linked dilatation in rat middle cerebral artery. Stroke 2005, 36(7):1526-1532.
32. Mendelsohn M.E., Karas R.H. Estrogen and the blood vessel wall. Curr. Opin. Cardiol. 1994, 9(5):619-626.
33. Meyer M.R., Baretella O., Prossnitz E.R., Barton M. Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780. Pharmacology 2010, 86(1):58-64.
34. Meyer R., Linz K.W., Surges R., Meinardus S., Vees J., Hoffmann A., Windholz O., Grohe C. Rapid modulation of L-type calcium current by acutely applied oestrogens in isolated cardiac myocytes from human, guinea-pig and rat. Exp. Physiol. 1998, 83(3):305-321.
35. Meyers M.J., Sun J., Carlson K.E., Marriner G.A., Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 2001, 44(24):4230-4251.
36. Montgomery S., Shaw L., Pantelides N., Taggart M., Austin C. Acute effects of oestrogen receptor subtype-specific agonists on vascular contractility. Br. J. Pharmacol. 2003, 139(7):1249-1253.
37. Morello K.C., Wurz G.T., DeGregorio M.W. SERMs: current status and future trends. Crit. Rev. Oncol. Hematol. 2002, 43(1):63-76.
38. Naderali E.K., Walker A.B., Doyle P., Williams G. Comparable vasorelaxant effects of 17alpha- and 17beta-oestradiol on rat mesenteric resistance arteries: an action independent of the oestrogen receptor. Clin. Sci. (Lond.) 1999, 97(6):649-655.
39. Noppens R.R., Kofler J., Hurn P.D., Traystman R.J. Dose-dependent neuroprotection by 17beta-estradiol after cardiac arrest and cardiopulmonary resuscitation. Crit. Care Med. 2005, 33(7):1595-1602.
40. Otter D., Austin C. Effects of 17beta-oestradiol on rat isolated coronary and mesenteric artery tone: involvement of nitric oxide. J. Pharm. Pharmacol. 1998, 50(5):531-538.
41. Paganini-Hill A. Estrogen replacement therapy-something to smile about. Compend. Contin. Educ. Dent. 1998, (Suppl. (22)):S4-S8.
42. Plahta W.C., Clark D.L., Colbourne F. 17beta-estradiol pretreatment reduces CA1 sector cell death and the spontaneous hyperthermia that follows forebrain ischemia in the gerbil. Neuroscience 2004, 129(1):187-193.
43. Prossnitz E.R., Sklar L.A., Oprea T.I., Arterburn J.B. GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol. Sci. 2008, 29(3):116-123.
44. Razandi M., Pedram A., Greene G.L., Levin E.R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol. 1999, 13(2):307-319.
45. Register T.C., Adams M.R. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J. Steroid Biochem. Mol. Biol. 1998, 64(3-4):187-191.
46. Russell K.S., Haynes M.P., Sinha D., Clerisme E., Bender J.R. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc. Natl. Acad. Sci. U.S.A. 2000, 97(11):5930-5935.
47. Salom J.B., Burguete M.C., Perez-Asensio F.J., Torregrosa G., Alborch E. Relaxant effects of 17-beta-estradiol in cerebral arteries through Ca(2+) entry inhibition. J. Cereb. Blood Flow Metab. 2001, 21(4):422-429.
48. Shaw L., Taggart M.J., Austin C. Mechanisms of 17 beta-oestradiol induced vasodilatation in isolated pressurized rat small arteries. Br. J. Pharmacol. 2000, 129(3):555-565.
49. Simoncini T., Fornari L., Mannella P., Varone G., Caruso A., Liao J.K., Genazzani A.R. Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase. Steroids 2002, 67(12):935-939.
50. Stauffer S.R., Coletta C.J., Tedesco R., Nishiguchi G., Carlson K., Sun J., Katzenellenbogen B.S., Katzenellenbogen J.A. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J. Med. Chem. 2000, 43(26):4934-4947.
51. Stirone C., Boroujerdi A., Duckles S.P., Krause D.N. Estrogen receptor activation of phosphoinositide-3 kinase, akt, and nitric oxide signaling in cerebral blood vessels: rapid and long-term effects. Mol. Pharmacol. 2005, 67(1):105-113.
52. Toung T.K., Hurn P.D., Traystman R.J., Sieber F.E. Estrogen decreases infarct size after temporary focal ischemia in a genetic model of type 1 diabetes mellitus. Stroke 2000, 31(11):2701-2706.
53. Tsang S.Y., Yao X., Essin K., Wong C.M., Chan F.L., Gollasch M., Huang Y. Raloxifene relaxes rat cerebral arteries in vitro and inhibits L-type voltage-sensitive Ca2+ channels. Stroke 2004, 35(7):1709-1714.
54. Volterrani M., Rosano G., Coats A., Beale C., Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am. J. Med. 1995, 99(2):119-122.
55. Wang Y.J., Lin M.W., Wu S.N., Sung R.J. The activation by estrogen receptor agonists of the BK(Ca)-channel in human cardiac fibroblasts. Biochem. Pharmacol. 2007, 73(9):1347-1357.
56. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(24):9063-9068.
57. Watters J.J., Campbell J.S., Cunningham M.J., Krebs E.G., Dorsa D.M. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 1997, 138(9):4030-4033.
58. White R.E., Darkow D.J., Lang J.L. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ. Res. 1995, 77(5):936-942.